Last reviewed · How we verify

NCT00564031: HRT

Hormonal Replacement Therapy and Small Artery Function

Completed Phase 3 Last updated 26 November 2007
What this trial tests

Phase 3 trial testing Femanest in Menopause in 66 participants. Completed in 1 August 2004.

Timeline
1 January 2003
1 August 2004

Quick facts

Lead sponsorKarolinska University Hospital
PhasePhase 3
StatusCompleted
Study typeINTERVENTIONAL
Allocationrandomized
Designparallel
Maskingdouble
Primary purposeprevention
Enrollment66
Start date1 January 2003
Estimated completion1 August 2004
Sites1 location across Sweden

Drugs / interventions tested

Conditions studied

Sponsor

Karolinska University Hospital

Who can join

Adults 50 to 60, female only, with Menopause. Healthy volunteers can join.

What's being measured

Primary outcomes are the specific endpoints the trial is designed to prove or disprove.

Sponsor's own description

Endothelial dysfunction in resistance arteries in women after the menopause is important for the development of high blood pressure and cardiovascular disease

Publications & conference data

No peer-reviewed publications indexed yet for this trial. Completed trials usually publish results within 12-18 months.

Verify or expand the search:

Other recruiting trials for Menopause

Currently open trials in the same condition.

Other Karolinska University Hospital trials

Trials by the same sponsor.

Verify against primary sources

Data sources for this page

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT00564031.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing